Pursuant to Regulation 34(1) of SEBI (LODR) Regulations, 2015, please find enclosed the Integrated Annual Report of the Company for the financial year 2024-25 along with the Notice convening ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Qualitek Labs, listed on BSE SME Emerge platform (Scrip Code: 544091), submitted the notice for its 7th AGM scheduled on September 25, 2025, at 11:30 AM in New Delhi, along with the Integrated Annual Report for FY 2024-25. The consolidated financials show strong growth: revenue jumped 2.4x to Rs 70.2 crore, Net Profit rose 1.8x to Rs 7.7 crore, EBITDA doubled to Rs 16.8 crore (24% margin), with EPS at Rs 7.08. Revenue grew at a 101% CAGR over FY21–FY25. The AGM agenda includes reappointment of Mr. Kamal Grover, appointment of Mr. Mangesh Bhosale as Whole-Time Director (Rs 30.27 lakh annual CTC) for 5 years, appointment of Mr. Ajay Agarwal as Independent Director for 5 years, an increase in Managing Director Mr. Antaryami Nayak's remuneration to Rs 2.25 lakh per month, appointment of Ronak Jhuthawat & Co. as Secretarial Auditor for 5 years, and an overall revision in director remuneration limits.
This is a routine AGM-related compliance filing, but it carries material shareholder items including director remuneration hikes and leadership appointments that require voting approval. The strong financial trajectory and stated 2x-every-2-years growth target, backed by ongoing acquisitions and lab expansion, is a positive signal for shareholders evaluating the stock's long-term prospects.